Social media

It is thought that someone in the world develops dementia every three seconds. ICON is a proud supporter of #WorldAlzheimer’sDay and has participated in 39 clinical studies in Alzheimer's disease and other dementias glob...

Are you wondering how ICON is using AI to address common delivery pain points? Join ICON’s Madelaine MacKay, ICON’s Senior Director, Product Delivery, at the 13th Annual OCT Southern California conference on 23 September...

As oncology biologics face expiring patents, biosimilar developers need to prepare for a new era of opportunity and market growth. In this article, ICON’s Kim Salgado examines the opportunities and regulatory shifts th...

As oncology biologics face expiring patents, biosimilar developers need to prepare for a new era of opportunity and market growth. In this article, ICON’s Kim Salgado examines the opportunities and regulatory shifts t...

Are weight loss endpoints enough to demonstrate the true impact of obesity treatments? Regulators and patients increasingly expect trials to capture outcomes that reflect the entire patient experience. Join ICON expe...

Are weight loss endpoints enough to demonstrate the true impact of obesity treatments? Regulators and patients increasingly expect trials to capture outcomes that reflect the entire patient experience. Join ICON expe...

Pediatric clinical trials have different processes, risks and challenges than adult trials. Identifying those differences is critical but can be difficult, especially if resources are limited. Join ICON’s Heather Peterso...

Clinical development processes for pediatric trials differ from adult trials. Register for our webinar to learn about regulatory strategies and tools needed to ensure pediatric access to medical treatment and an interact...

World Cancer Research Day, observed on September 24, reminds us that progress in oncology depends on continued research. Breakthroughs like combination therapies are transforming care, improving outcomes and extending li...

As clinical trials become more complex, risk management must evolve. Join Victoria DeVeaugh-Geiss and fellow industry experts as they explore the evolution of RBQM. https://ow.ly/j0aW50WXtj0

As clinical trials become more complex, risk management must evolve. Join Victoria DeVeaugh-Geiss and fellow industry experts as they explore the evolution of RBQM. https://ow.ly/rFNW50WXtiZ

Are your systems and processes ready for ICH GCP E6(R3)? From participant protection to technology use, these updates reshape every aspect of clinical trial processes. Our new whitepaper outlines what has changed and ho...